Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Schedules Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 202617.3.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / March 17, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset tokenization technologies, today announced that it will report financial results for its fourth quarter and full year 2025 prior to market open on Thursday, March 19, 2026. Following the release, Datavault AI will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Thursday, March 19, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-405-1216 Participant Dial-in (International): 1-201-689-8336 Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here. About Datavault AI Inc. Datavault AI TM (NASDAQ:DVLT) is leading the
Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense16.3.2026 13:30:00 CET | Press release
UK-Based Rotron Aerospace Strengthens Ondas' Systems of Systems Architecture with Unmanned Aircraft Platforms, Aero-Engine Technologies, and Long-Endurance Autonomous Mission Capabilities Expands Ondas' Strategic Footprint Within the UK and NATO Ecosystems, Providing Fast-Track Access to Major Programs Through Deep-Rooted Relationships with the UK Ministry of Defence Establishes a UK Industrial Base for Advanced Unmanned Systems Supporting NATO Programs and Allied Defense Localization Initiatives WEST PALM BEACH, FL AND LONDON, UK / ACCESS Newswire / March 16, 2026 / Ondas Inc. (Nasdaq:ONDS) ("Ondas" or the "Company"), a leading provider of autonomous aerial and ground robot intelligence through its Ondas Autonomous Systems (OAS) business unit and private wireless solutions through Ondas Networks, today announced the completion of its acquisition of Rotron Aerospace Ltd. (Rotron), a UK-based developer of advanced unmanned aerial systems and long-range autonomous platforms designed for
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
LiberNovo: From Spring Cleaning to Physical Renewal12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / As the annual ritual of spring cleaning approaches, a new movement in functional design is shifting the focus from tidying desks to restoring the bodies that sit at them. LiberNovo, a pioneer in health-first design, has announced its spring initiative: a fundamental reimagining of the smart workspace that prioritizes physical fluidity over static organization. New Season, New Standards For decades, office chair ergonomics centered on the "90-degree rule"-a rigid posture that modern research suggests is counterproductive. The true culprit of office fatigue isn't just sitting; it is the lack of movement. Prolonged static positions compress the spine and reduce circulation. LiberNovo's philosophy asserts that a "Spring Reset" is incomplete if it only addresses surface-level clutter while leaving the body in a state of constant strain. Engineering Movement At the core of this movement is the LiberNovo Omni, a chair designed to master Dynam
LiberNovo Omni Wins iF DESIGN AWARD 2026 for Breakthrough Ergonomic Design12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / LiberNovo is proud to announce that its leading product, the LiberNovo Omni, has won the prestigious iF DESIGN AWARD 2026 in the Product Design - Beauty/Wellness category. The iF DESIGN AWARD is one of the most esteemed design competitions in the world, honoring outstanding design achievements in terms of innovation, functionality, and user experience. Developed to revolutionize the experience of sitting for long periods, the LiberNovo Omni is a product that creates a new category of seating solutions: the Dynamic Ergonomic Chair. The chair doesn't lock people into fixed positions; it accommodates natural body positions and movement throughout the day. This award-winning chair features intelligent ergonomic technologies to enhance user comfort, spinal health, and support movement. These include LiberNovo's innovative Dynamic Support, which automatically adjusts to changing postures, and an adjustable ergonomic framework designed to ens
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom